Resveratrol is a polyphenol found at high concentrations in grapes and red wine with reported anticarcinogenic effects. We studied the molecular mechanism of resveratrol-induced apoptosis and proliferation arrest in prostate derived cells PZ-HPV-7 (non-tumorigenic line), LNCaP (androgen-sensitive cancer line) and PC-3 (androgen-insensitive cancer line). Apoptosis and cell cycle distribution were evaluated by flow cytometry and proliferation by MTT assay and direct cell counting. Caspases, bax, bcl-2, cyclins, Cdks, p53, p21 and p27 were measured by western blot and kinase activities of cyclin/Cdk complexes by immunoprecipitation followed by kinase assays with appropriate substrates. Resveratrol induced a decrease in proliferation rates and an increase in apoptosis in cancer cell lines in a dose-and time-dependent manner. These effects were coincident with cell accumulation at the G0/G1 phase. In LNCaP and PC-3, the apoptosis induced by resveratrol was mediated by activation of caspases 9 and 3 and a change in the ratio of bax/bcl-2. Expressions of cyclin D1, E and Cdk4 as well as cyclin D1/Cdk4 kinase activity were reduced by resveratrol only in LNCaP cells. In contrast, cyclin B and Cdk1 expression and cyclin B/Cdk1 kinase activity were decreased in both cell lines in presence of resveratrol. However, modulator proteins p53, p21 and p27 were increased by resveratrol only in LNCaP cells. These effects probably result in the observed proliferation arrest and disruption of cell cycle control. In addition, the specific differences found between LNCaP and PC-3 suggest that resveratrol acts through different mechanisms upon the androgen or estrogen receptor cell status.
Introduction
Prostate carcinoma is one of the most common malignancies and represents the second cause of cancer-related deaths in men wideworld (Forti and Selli, 1996; Long et al, 1997) . At the beginning, prostate cancer is asymptomatic and late diagnosis is usual. Because many malignant prostate tumors are androgen sensitive, testosterone ablation represents the main therapy of localized and early metastatic tumors (Aquilina et al, 1997; Cunha et al, 1987; Wilding, 1992) . However, advanced stages usually become androgen insensitive with practically no therapeutic options.
Some epidemiologic studies have shown that nutritional factors may be related with carcinogenesis. Occidental fat-enriched diet correlates with high risk of prostate and other cancers, while oriental diet based on vegetables, fruit and seeds are related with lower cancer risk (Adlercreutz and Mazur, 1997; Clinton and Giovannucci, 1998; Hsing et al, 2000; Romero Cagigal et al, 2003) . Considering these data, a chemopreventive role for natural compounds present in natural food has been proposed. Among these substances, polyphenolic antioxidants have received increasing attention in the last years. One of such naturally occurring polyphenol is resveratrol, which is present in peanuts, grapes and red wine (Fremont, 2000; Sanders et al, 2000; Sobolev and Cole, 1999) . Also, epidemiologic studies have suggested that regular and moderate red wine consumption could have beneficial effects in human health (Goldberg et al, membranes and activating caspase-9 in leukemia cells (Dorrie et al, 2001 ). However, in the prostate cancer cell line LNCaP the effect of resveratrol on caspase activation has not been conclusively demonstrated.
Another suggested target for resveratrol action is the control of the cell cycle. Recent data have shown that resveratrol inhibits tumor development and cellular proliferation in cancerderived cell lines (Dorrie et al, 2001; Mgbonyebi et al, 1998; Tinhofer et al, 2001 ). This antiproliferative activity of resveratrol has also been shown to involve apoptosis induction in cancer cells (Ahmad et al, 2001; Dorrie et al, 2001; Tinhofer et al, 2001 ). In the estrogendependent mammary MCF-7 cells, resveratrol diminishes cell viability and induces apoptosis by modulating the expression and activity of relevant cell cycle regulators (Pozo-Guisado et al, 2002) . It has been shown that resveratrol induces cell cycle arrest in prostate cell lines PC-3 and DU-145 (androgen insensitive) but not in LNCaP (androgen sensitive), probably by disruption of the G1/S transition (Sgambato et al, 2001 ). Similar results have been reported in DU-145 cells using polyphenolic extracts from grape seed (Agarwal et al, 2000) . Resveratrol has structural similarity with both androgens and estrogens and there is evidence that some of its effects might be mediated by steroid hormone receptors (Bowers et al, 2000; Gehm et al, 1997; Kampa et al, 2000) . Normal prostate cells express androgen and, in less extent, estrogen receptors (Latil et al, 2001; Leav et al, 2001; Royuela et al, 2001 ). However, in prostate cancer cells, estrogen receptors are usually overexpressed and androgen receptor, although present in sensitive stages, it is normally mutated or absent in advanced metastatic disease (Culig et al, 1993; Veldscholte et al, 1990) . Moreover, some effects of resveratrol might be mediated by other mechanism related with its antioxidant capacity.
In the present work, we studied the mechanisms involved in resveratrol-induced proliferation arrest and apoptosis in prostate cancer, comparing non-tumorigenic, androgen sensitive and androgen insensitive cancer cell lines. for 1-10 min. In order to detect a second protein, some blots were stripped by incubation with 100 mM Tris-HCl, pH 7.4, 100 mM β-mercaptoethanol, and 2% SDS at 60 °C for 30 min.
Immunoprecipitation and kinase assay
Cultures were grown in 100 mm dishes and treated with solvent (DMSO), 1, 10, 50, 100, or 150 μM resveratrol for 36 hr. Cells were then lysed on ice for 10 min with 500 μL IP buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P40) containing 1 mM phenyl-methyl sulfonyl fluoride, 1 mM sodium orthovanadate, 1 mM NaF, 10 mM β-glycerophosphate, 1 mM DTT, and 4 µg/µL complete protease inhibitor cocktail. After brief mixing, lysates were centrifuged at 15,000 g for 15 min at 4°C, pellets were discarded and protein concentration determined in the supernatants as indicated above. An amount of 500 μg protein was used for each immunoprecipitation reaction. To eliminate non-specific binding, lysates were pre-incubated for 1 hr at 4°C with 20 μL protein A/G Plus-agarose beads. After removing the beads by centrifugation, cell lysates were rotated overnight at 4°C with 1 μg anti-cyclin D1 or anti-Cdk1 polyclonal antibodies. Extracts were then incubated at 4°C for an additional 60 min with 30 μL protein A/G Plus-agarose beads. Beads were washed three times in IP buffer and twice in kinase buffer (20 mM Tris-HCl pH 8.0, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT) and finally resuspended in a total volume of 10 μL of kinase buffer. In vitro kinase activity was assayed at 30°C for 30 min in 25 μL kinase buffer containing 10 μL protein A/G Plus-agarose beads, 1 mM NaF, 1 mM sodium-orthovanadate, 1 μg GST-Rb or 5 μg Histone H1 target proteins, 10 μCi 32 P-γ-ATP (sp. act. 3000 Ci/mmol), and 1 mM non-labeled ATP. After the reaction was completed, SDS-sample buffer was added and samples boiled for 5 min. The levels of phosphorylated GSTRb or Histone H1 were determined by SDS-PAGE electrophoresis and autoradiography using phosphor-screens on a Molecular Imager FX-System (BioRad Laboratories, Hercules, CA). 
Statistical analysis
Data were expressed as mean ± SEM. Statistical comparison between treatments was carried out using GraphPad Prism 4.0 (GraphPad Software, Inc, San Diego, CA). One-way ANOVA followed by Dunn test was applied with significances of p < 0.05*, p < 0.01**, p < 0.001***.
Results

Resveratrol inhibited cell growth in normal and prostate cancer cell lines
Prostate cancer cells (LNCaP and PC-3) and PZ-HPV-7 non-tumorigenic human prostate epithelial cells were treated with 0-150 µM of resveratrol during 12 -72 hrs and the cell number was estimated by MTT assay, as indicated in the methods. The treatment of LNCaP ( Figure 1A) and PC-3 ( Figure 1B ) prostate cancer cells with resveratrol resulted in a dose-and timedependent inhibition of cell proliferation as previously reported (Hsieh and Wu, 1999; Kampa et al, 2000) . However, growth inhibition resulted more potent in cancer cells than non-tumorigenic cells. Thus, whereas in LNCaP and PC-3 cells resveratrol significantly decreased their proliferation rate at short times, in PZ-HPV-7 cells, no effect was found until 24 hrs treatment with concentrations of resveratrol above 100 µM ( Figure 1C ). From these results, we selected resveratrol treatments for 36 hr in all cell lines. A similar effect of resveratrol on the cell number was also determined by cell counting using a hemocytometer (results not shown). When these cell lines were treated with resveratrol for 36 h (Figure 2A ), a reduction in the number of cells could be observed that was more pronounced in PC-3 than in LNCaP than in PZ-HPV-7. These results are in agreement with those presented in Figure 1 .
Resveratrol-induced changes in cell cycle distribution in prostatic cancer cells
To analyze whether resveratrol-induced inhibition of cell growth in prostate cancer cell lines was accompanied by alterations in cell cycle distribution, we analyzed the percentage of 
Effect of resveratrol on modulators of the cell cycle, p53, p21 and p27
Since inhibitory mechanism of resveratrol on cell proliferation might also affect the expression of negative regulators of the cell cycle, we evaluated protein expression of p53, p21 and p27. The p21 and p27 are inhibitors of cyclin/Cdk complexes mainly involved in G1/S transition. All 3 proteins were significantly increased by resveratrol in a dose-dependent manner in LNCaP cells ( Figure 5A ), while in PC-3 cells there were no significant changes in protein expression of p21 and p27 at the concentrations of resveratrol used ( Figure 5B ).
Apoptosis induction by resveratrol
To analyze whether the antiproliferative activity of resveratrol in LNCaP and PC-3 cell lines was associated to increased apoptosis, the apoptotic index was determined by flow cytometry. By measuring the fraction of cells with sub G0/G1 DNA content, we observed that concentrations of resveratrol below 50 µM did not induce a significant level of apoptosis in any of the cell lines analyzed. Increasing the concentration of this molecule to 100 µM and 150 µM increased apoptosis rates to maximum values of 50% and 20% for LNCaP and PC-3, respectively ( Figure 6A, B) . The non-tumorigenic prostate PZ-HPV-7 cell line had a higher level of basal apoptosis (about 10%) that was not affected by resveratrol at any of the concentrations used. Thus, the antiproliferative effect of resveratrol was associated to apoptosis mainly in androgen-dependent LNCaP cells.
Resveratrol-induced apoptosis is mediated by caspase activation
To further characterize this cell-specific apoptotic effect of resveratrol in prostatic cancer cells, we analyzed the activation of caspases and the levels of total bax and bcl-2 proteins. For this purpose, LNCaP and PC-3 cells were plated on 100 mm culture dishes and treated with resveratrol or DMSO for 36 hr and total protein analyzed by SDS-PAGE. We observed that caspase 9 was significantly activated by resveratrol in LNCaP and PC-3 cells. Active caspase 8 was slightly increased by high doses of resveratrol only in PC-3 cells. As expected, effector caspase 3 was activated in both cell lines by resveratrol in a dose-dependent manner ( Figure   6C ). In LNCaP cells, proapoptotic regulator bax increased with resveratrol treatments whereas antiapoptotic bcl-2 protein markedly decreased even at low concentrations of resveratrol. In contrast, in PC-3 cells only bcl-2 significantly decreased by resveratrol treatment with no important changes in bax level ( Figure 6D ).
Discussion
Polyphenolic compounds naturally occurring in diets rich in fruits, vegetables and seeds have been proposed as chemopreventive agents against a variety of diseases including cancer (Clement et al, 1998; Damianaki et al, 2000; Kang et al, 2003; Mazzon et al, 2005; Scalbert et al, 2005; Schneider et al, 2000; Yi et al, 2005) . Resveratrol, one of these polyphenols present at high levels in grapes and red wine, has been extensively studied regarding its effects on several malignancies including prostate cancer (Boissy et al, 2005; Garvin et al, 2006; Hsieh and Wu, 1999; Schneider et al, 2000; Signorelli and Ghidoni, 2005; Vyas et al, 2006; Zunino and Storms, 2005) . Resveratrol has a high structural homology with androgens and estrogens, and there is convincing evidence that, at least some of its effects might be mediated by steroid receptors (Bowers et al, 2000; Gao et al, 2004) However, the molecular mechanism involved in resveratrol-induced apoptosis appears to be different since it was not mediated by caspase activation in MCF-7 breast tumor cells (PozoGuisado et al, 2005) . Data on caspase activation by resveratrol in prostate cell lines are not conclusive, but in leukemia cells, resveratrol-induced activation of the mitochondrial pathway involving caspase-9 activity has been reported (Dorrie et al, 2001 ). On the other hand, a marked increase in proapoptotic bax protein and a decrease in antiapoptotic bcl-2 were induced by resveratrol in LNCaP. This result is in accordance with a recent report showing that resveratrol induced a inhibition of PI3K pathway followed by a decrease in the level of bcl-2 and an increase in However, the activation of the intrinsic apoptotic pathway is related with changes in the ratio of both proteins rather than with individual variations (Korsmeyer et al, 1993; Pozo-Guisado et al, 2002; Reed, 1994) . Therefore, our results suggest that resveratrol induced apoptosis in LNCaP and PC-3 prostate cancer cells through alteration of the bax/bcl-2 balance and through activation of caspase 9, both processes leading to increased caspase 3 activity. In agreement, LNCaP cells, which had higher levels of caspase-9, -8 and -3 activities, and elevated bax/bcl-2 ratio, also had increased apoptosis rates with respect to PC-3 cells. Considering that resveratrol can interact with both androgen and estrogen receptors (Gehm et al, 1997) and that LNCaP cells express androgen receptor whereas PC-3 cells have estrogen receptors alpha/beta, the differential interaction of resveratrol with these two type of receptors may account for the differences in the molecular mechanism showed in both cell lines. In this regard, resveratrol appears to inhibit the G1/S transition more efficiently in LNCaP than in PC-3 cells, an effect that might also help to explain the higher sensitivity to apoptosis in androgen responsive LNCaP cells. A cell-specific mechanism of resveratrol action has been also shown in MCF-7 and MDA-MB-231 human breast cancer cells, in which apoptosis was also induced in estrogen-responsive MCF-7 but not in estrogen-unresponsive MDA-MB-231 cells (PozoGuisado et al, 2002; Pozo-Guisado et al, 2004) . However, the presence of a very low level of beta-estrogen receptor expression in LNCaP cells may not disregard completely its influence, but taking in account the differences in the level of expression in both cells, we consider that our suggestion is highly probably. We are currently studying this issue. Analyzing upstream modulators of cyclin/Cdk complexes, we have found that p21 and p27 were increased by resveratrol only in LNCaP cells. Consistently, the key cell cycle regulator p53 was also increased by resveratrol in this cell line. P53-dependent gene expression, as androgen receptor coactivators and activation of NFkB induced by resveratrol in LNCaP cells have also been reported (Narayanan et al, 2003) . In addition, resveratrol induced, via MAPK pathway, a phosphorylation of p53 followed by an increase in p21, in a mutant p53 prostate cancer cell line (Lin et al, 2002) .These data confirm that p53 and p21 (as p27 and others cell cycle regulators) are very pleiotropic proteins and are related with several molecular pathways. Considering that p21 and p27 proteins inhibit mainly G1-S cyclin/Cdk complexes, we speculate that resveratrol may be affecting the cell cycle of PC-3 cells through others regulators. Taken together, the data presented in this work indicate that resveratrol induces caspase 9-mediated apoptosis with changes in the bax/bcl-2 ratio, and proliferation arrest through disruption of the G1/S and G2/M transitions. Nevertheless, the molecular mechanism of resveratrol may be different in cancer cells representative of different malignancy grades. We suggest that these differences might be explained by the distinct profile of steroid receptors present in these cell lines. Our results reinforce the use of resveratrol in the chemoprevention of prostate cancer. Although, chemopreventive action of grape juice or red wine on healthy cells is not only due to resveratrol but also to other numerous polyphenolic compounds like gallic acid, quercetin, catequin, among others, resveratrol concentration in red wine may reach over 4 mg/L. However, data presented in this work strongly suggest that resveratrol may have therapeutic potential on malignant cells and it could be used as a pharmacological preparation. From this perspective the potential toxicity of resveratrol in vivo is a major issue. There are very few studies on resveratrol toxicity in vivo.
Recently, it has been reported that only at high doses (3 g/Kg/day), resveratrol causes moderate liver toxicity as measured by DNA array and induction of phase II metabolizing enzymes (Hebbar et al, 2005) . This potentially toxic concentration is far beyond the doses used in this study. 
